- Home
- MURA vs MRSN Comparison
MURA vs MRSN Comparison
Compare MURA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- MRSN
- Stock Information
- Founded
- MURA 2013
- MRSN 2001
- Country
- MURA Ireland
- MRSN United States
- Employees
- MURA N/A
- MRSN N/A
- Industry
- MURA
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- MRSN Health Care
- Exchange
- MURA Nasdaq
- MRSN Nasdaq
- Market Cap
- MURA N/A
- MRSN 71.9M
- IPO Year
- MURA N/A
- MRSN 2017
- Fundamental
- Price
- MURA $1.26
- MRSN $0.35
- Analyst Decision
- MURA Strong Buy
- MRSN Buy
- Analyst Count
- MURA 5
- MRSN 3
- Target Price
- MURA $13.00
- MRSN $4.00
- AVG Volume (30 Days)
- MURA 419.4K
- MRSN 3.2M
- Earning Date
- MURA 03-11-2025
- MRSN 03-03-2025
- Dividend Yield
- MURA N/A
- MRSN N/A
- EPS Growth
- MURA N/A
- MRSN N/A
- EPS
- MURA N/A
- MRSN N/A
- Revenue
- MURA N/A
- MRSN $40,497,000.00
- Revenue This Year
- MURA $79.64
- MRSN N/A
- Revenue Next Year
- MURA N/A
- MRSN $67.68
- P/E Ratio
- MURA N/A
- MRSN N/A
- Revenue Growth
- MURA N/A
- MRSN 9.88
- 52 Week Low
- MURA $1.12
- MRSN $0.37
- 52 Week High
- MURA $5.02
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- MURA 19.38
- MRSN 30.36
- Support Level
- MURA $3.77
- MRSN $0.41
- Resistance Level
- MURA $4.35
- MRSN $0.42
- Average True Range (ATR)
- MURA 0.26
- MRSN 0.04
- MACD
- MURA -0.30
- MRSN 0.00
- Stochastic Oscillator
- MURA 4.92
- MRSN 5.62
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.